Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727871 | 0.83 | AURKA (0.34) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL1425157 | 0.76 | KMT2A (0.35) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL1727074 | 0.76 | NOS3 (0.47) | HDAC1HDAC6HDAC3HDAC2PIK3CA | |
| SCHEMBL4390565 | 0.76 | ATM (0.51) | — | |
| SCHEMBL608534 | 0.74 | GPR183 (0.36) | HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL3430654 | 0.74 | HCAR2 (0.44) | CTSA | |
| SCHEMBL27248266 | 0.74 | PIK3R1 (0.32) | PIK3CAPIK3R1MTORCTSAMGLL | |
| SCHEMBL931895 | 0.72 | C1S (0.41) | — | |
| SCHEMBL3463153 | 0.70 | RECQL (0.41) | PIK3CAPIK3R1MTOR | |
| SCHEMBL9953743 | 0.70 | CNR2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | HDAC1 1246/4885HDAC6 1079/4885HDAC3 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.